PREPIDIL Gel is generally well-tolerated. In controlled trials, in which 1731 women were entered, the following events were reported at an occurrence of ≥ 1%:
| Adverse Reaction | PGE2 (N = 884) | Control* (N = 847) |
|---|---|---|
| ||
| Maternal | N (%) | N (%) |
| Uterine contractile abnormality | 58 (6.6) | 34 (4.0) |
| Any gastrointestinal effect | 50 (5.7) | 22 (2.6) |
| Back pain | 27 (3.1) | 0 (0) |
| Warm feeling in vagina | 13 (1.5) | 0 (0) |
| Fever | 12 (1.4) | 10 (1.2) |
| Fetal | ||
| Any fetal heart rate abnormality | 150 (17.0) | 123 (14.5) |
| Bradycardia | 36 (4.1) | 26 (3.1) |
| Deceleration | ||
| Late | 25 (2.8) | 18 (2.1) |
| Variable | 38 (4.3) | 29 (3.4) |
| Unspecified | 19 (2.1) | 19 (2.2) |
In addition, in other trials amnionitis and intrauterine fetal sepsis have been associated with extra-amniotic intrauterine administration of PGE2. Uterine rupture has been reported in association with the use of PREPIDIL Gel intracervically. Additional events reported in the literature, associated by the authors with the use of PREPIDIL Gel, included premature rupture of membranes, fetal depression (1 min Apgar < 7), and fetal acidosis (umbilical artery pH < 7.15).
An increased risk of post-partum disseminated intravascular coagulation has been described in patients whose labor was induced by pharmacological means, either with dinoprostone or oxytocin (see WARNINGS). The frequency of this adverse event, however, appears to be rare (<1 per 1,000 labors).
PREPIDIL Gel is generally well-tolerated. In controlled trials, in which 1731 women were entered, the following events were reported at an occurrence of ≥ 1%:
| Adverse Reaction | PGE2 (N = 884) | Control* (N = 847) |
|---|---|---|
| ||
| Maternal | N (%) | N (%) |
| Uterine contractile abnormality | 58 (6.6) | 34 (4.0) |
| Any gastrointestinal effect | 50 (5.7) | 22 (2.6) |
| Back pain | 27 (3.1) | 0 (0) |
| Warm feeling in vagina | 13 (1.5) | 0 (0) |
| Fever | 12 (1.4) | 10 (1.2) |
| Fetal | ||
| Any fetal heart rate abnormality | 150 (17.0) | 123 (14.5) |
| Bradycardia | 36 (4.1) | 26 (3.1) |
| Deceleration | ||
| Late | 25 (2.8) | 18 (2.1) |
| Variable | 38 (4.3) | 29 (3.4) |
| Unspecified | 19 (2.1) | 19 (2.2) |
In addition, in other trials amnionitis and intrauterine fetal sepsis have been associated with extra-amniotic intrauterine administration of PGE2. Uterine rupture has been reported in association with the use of PREPIDIL Gel intracervically. Additional events reported in the literature, associated by the authors with the use of PREPIDIL Gel, included premature rupture of membranes, fetal depression (1 min Apgar < 7), and fetal acidosis (umbilical artery pH < 7.15).
An increased risk of post-partum disseminated intravascular coagulation has been described in patients whose labor was induced by pharmacological means, either with dinoprostone or oxytocin (see WARNINGS). The frequency of this adverse event, however, appears to be rare (<1 per 1,000 labors).
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.